EA201490039A1 - Химерные и гибридные полипептиды фактора viii и способы их применения - Google Patents

Химерные и гибридные полипептиды фактора viii и способы их применения

Info

Publication number
EA201490039A1
EA201490039A1 EA201490039A EA201490039A EA201490039A1 EA 201490039 A1 EA201490039 A1 EA 201490039A1 EA 201490039 A EA201490039 A EA 201490039A EA 201490039 A EA201490039 A EA 201490039A EA 201490039 A1 EA201490039 A1 EA 201490039A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hybrid polypeptides
factor viii
methods
chemeric
application
Prior art date
Application number
EA201490039A
Other languages
English (en)
Other versions
EA029045B1 (ru
Inventor
Дженнифер А. Дьюмонт
Сьюзен Лоу
Алан Дж. Битонти
Гленн Пирс
Элвин Люк
Хайянь Цзян
Байрон Маккинни
Мэтт Оттмер
Юрг Зоммер
Карен Ньюджент
Лиан Ли
Роберт Питерс
Original Assignee
Байоджен Айдек Хемофилия Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Хемофилия Инк. filed Critical Байоджен Айдек Хемофилия Инк.
Publication of EA201490039A1 publication Critical patent/EA201490039A1/ru
Publication of EA029045B1 publication Critical patent/EA029045B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение предоставляет способы введения фактора VIII (процессированного FVIII, одноцепочечного FVIII или их комбинации); способы введения химерных и гибридных полипептидов, включающих фактор VIII; химерные и гибридные полипептиды, включающие фактор VIII; полинуклеотиды, кодирующие такие химерные и гибридные полипептиды; клетки, включающие такие полинуклеотиды; и способы получения таких химерных и гибридных полипептидов с использованием таких клеток.
EA201490039A 2011-07-08 2012-07-06 Химерные и гибридные полипептиды фактора viii и способы их применения EA029045B1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161506015P 2011-07-08 2011-07-08
US201161522647P 2011-08-11 2011-08-11
US201161541561P 2011-09-30 2011-09-30
US201161569158P 2011-12-09 2011-12-09
US201261586443P 2012-01-13 2012-01-13
US201261622789P 2012-04-11 2012-04-11
US201261657641P 2012-06-08 2012-06-08
PCT/US2012/045784 WO2013009627A2 (en) 2011-07-08 2012-07-06 Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201490039A1 true EA201490039A1 (ru) 2014-06-30
EA029045B1 EA029045B1 (ru) 2018-02-28

Family

ID=47506823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490039A EA029045B1 (ru) 2011-07-08 2012-07-06 Химерные и гибридные полипептиды фактора viii и способы их применения

Country Status (27)

Country Link
US (3) US10010622B2 (ru)
EP (3) EP2729161B1 (ru)
JP (5) JP2014522838A (ru)
KR (2) KR101829603B1 (ru)
CN (2) CN107261122A (ru)
AR (1) AR087091A1 (ru)
AU (3) AU2012282875B2 (ru)
BR (1) BR112014000466A2 (ru)
CA (1) CA2841066C (ru)
CL (1) CL2014000024A1 (ru)
CO (1) CO6940381A2 (ru)
CY (1) CY1122900T1 (ru)
DK (2) DK3513804T3 (ru)
EA (1) EA029045B1 (ru)
ES (2) ES2913994T3 (ru)
HR (2) HRP20220639T1 (ru)
HU (1) HUE043763T2 (ru)
IL (2) IL230333B (ru)
LT (2) LT2729161T (ru)
MX (1) MX350581B (ru)
MY (1) MY180714A (ru)
PL (2) PL2729161T3 (ru)
PT (2) PT2729161T (ru)
RS (2) RS58578B1 (ru)
SI (2) SI3513804T1 (ru)
TW (3) TWI626947B (ru)
WO (1) WO2013009627A2 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298347B1 (en) * 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
ES2880038T3 (es) 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
RS58578B1 (sr) * 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
EP3453402B1 (en) * 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
JP6317328B2 (ja) 2012-04-11 2018-04-25 ビオベラティブ テラポイティクス インコーポレーテッドＢｉｏｖｅｒａｔｉｖ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． グリコサミノグリカンを検出する方法
CN104427995A (zh) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 嵌合凝血因子
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
LT2968477T (lt) * 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Faktoriaus viii polipeptido kompozicijos
US9984348B2 (en) 2013-11-29 2018-05-29 Fedex Corporate Services, Inc. Context management of a wireless node network
US10453023B2 (en) 2014-05-28 2019-10-22 Fedex Corporate Services, Inc. Methods and node apparatus for adaptive node communication within a wireless node network
US11238397B2 (en) 2015-02-09 2022-02-01 Fedex Corporate Services, Inc. Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node
US10305744B2 (en) 2015-07-08 2019-05-28 Fedex Corporate Services, Inc. System, apparatus, and methods of event monitoring for an event candidate related to an ID node within a wireless node network
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
JP6957496B2 (ja) 2016-03-23 2021-11-02 フェデックス コーポレイト サービシズ，インコーポレイティド 無線ノードネットワーク内のノードのブロードキャスト設定を自動調整するための無線ノードベースの方法、その方法を実行する命令を含む非一時的コンピュータ可読媒体、および無線ノードネットワークにおける自動調整ブロードキャストノード装置
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
AU2018366110A1 (en) 2017-11-07 2020-06-04 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
EP3765064A1 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765053A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765065A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019191519A1 (en) * 2018-03-28 2019-10-03 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
JP2021523878A (ja) * 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
JP2022530615A (ja) * 2019-05-03 2022-06-30 ラニ セラピューティクス， エルエルシー 嚥下可能な薬物送達デバイスを使用する腸管の組織への送達のための凝固因子調製物
TW202115127A (zh) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 治療血友病及低骨質密度之方法及組成物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (ja) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
CA2461443C (en) * 2001-10-05 2011-07-12 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2006053299A2 (en) 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG123635A1 (en) 2004-12-28 2006-07-26 Nanoscience Innovation Pte Ltd Nanostructured zinc oxide and a method of producing the same
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
WO2007103455A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
ES2880038T3 (es) * 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos
MX2013000301A (es) * 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
WO2012006623A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
RS58578B1 (sr) * 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu

Also Published As

Publication number Publication date
JP2019048877A (ja) 2019-03-28
KR20180020305A (ko) 2018-02-27
US20140294821A1 (en) 2014-10-02
SI3513804T1 (sl) 2022-07-29
ES2913994T3 (es) 2022-06-07
US20210220476A1 (en) 2021-07-22
WO2013009627A3 (en) 2013-03-07
JP2023134851A (ja) 2023-09-27
AU2012282875B2 (en) 2016-04-21
US10881742B2 (en) 2021-01-05
US10010622B2 (en) 2018-07-03
CL2014000024A1 (es) 2014-11-21
PT2729161T (pt) 2019-04-01
TW202042838A (zh) 2020-12-01
CY1122900T1 (el) 2021-05-05
IL271870A (en) 2020-02-27
CN107261122A (zh) 2017-10-20
AU2012282875A1 (en) 2013-05-02
JP2017088623A (ja) 2017-05-25
SI2729161T1 (sl) 2019-05-31
EP3513804A1 (en) 2019-07-24
RS58578B1 (sr) 2019-05-31
MX2014000202A (es) 2014-10-06
EP2729161A2 (en) 2014-05-14
HRP20220639T1 (hr) 2022-07-08
AR087091A1 (es) 2014-02-12
IL230333B (en) 2020-05-31
IL271870B (en) 2022-04-01
HRP20190535T1 (hr) 2019-05-17
EP2729161A4 (en) 2015-06-24
ES2722209T3 (es) 2019-08-08
HUE043763T2 (hu) 2019-09-30
CO6940381A2 (es) 2014-05-09
AU2018202936B2 (en) 2020-07-02
NZ619438A (en) 2016-06-24
TWI687226B (zh) 2020-03-11
TW201315480A (zh) 2013-04-16
MY180714A (en) 2020-12-07
US20180360982A1 (en) 2018-12-20
EP2729161B1 (en) 2018-12-19
JP7273487B2 (ja) 2023-05-15
CA2841066A1 (en) 2013-01-17
JP2014522838A (ja) 2014-09-08
KR102110736B1 (ko) 2020-05-14
LT2729161T (lt) 2019-04-10
EP3513804B1 (en) 2022-03-23
DK2729161T3 (en) 2019-04-08
TWI764092B (zh) 2022-05-11
TWI626947B (zh) 2018-06-21
BR112014000466A2 (pt) 2017-02-21
PT3513804T (pt) 2022-06-02
MX350581B (es) 2017-09-11
EA029045B1 (ru) 2018-02-28
CN103796670A (zh) 2014-05-14
AU2016204986A1 (en) 2016-08-04
LT3513804T (lt) 2022-05-25
WO2013009627A2 (en) 2013-01-17
JP2022003096A (ja) 2022-01-11
PL3513804T3 (pl) 2022-07-11
PL2729161T3 (pl) 2019-08-30
RS63241B1 (sr) 2022-06-30
CA2841066C (en) 2023-09-26
AU2016204986B2 (en) 2018-05-10
KR101829603B1 (ko) 2018-02-19
AU2018202936A1 (en) 2018-05-17
KR20140066157A (ko) 2014-05-30
EP4169525A1 (en) 2023-04-26
TW201822788A (zh) 2018-07-01
DK3513804T3 (da) 2022-06-20

Similar Documents

Publication Publication Date Title
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
EA201492101A1 (ru) Антитела против fcrn
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2013009362A (es) Anticuerpo contra el csf-1r.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
IN2015DN03132A (ru)
MX362393B (es) Cassette de expresion.
GB201113880D0 (en) Novel compositions
MX2015010006A (es) Purificacion de proteinas mejorada a traves de una etapa de desglicosilacion.
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM